Seminars in Oncology
Volume 30, Issue 6 , Pages 740-748 , December 2003

Second cancers after breast cancer treatment

  • Sister Mary Andrew Matesich

      Affiliations

    • Ohio Dominican College, Columbus, OH, USA
    • ,
  • Charles L Shapiro

      Affiliations

    • Ohio State University Medical Center and Comprehensive Cancer Center, Columbus, OH, USA
    • Corresponding Author InformationAddress reprint requests to Charles L. Shapiro, MD, Associate Professor of Medicine, Director of Breast Medical Oncology, Ohio State University Medical Center and Comprehensive Cancer Center, Starling-Loving Hall, Room B405, 320 W 10th St, Columbus, OH 43210 USA

References 

  1. Shapiro CL, Recht A. Late effects of adjuvant therapy for breast cancer. JNCI Monogr. 1994;16:101–112
  2. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med. 2001;344:1997–2008
  3. Hayden GF, Kramer MS, Horwitz RI. The case-control study. A practical review for the clinician. JAMA. 1982;247:326–331
  4. Fisher B, Rockette H, Fisher ER, et al.  Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation (The NSABP experience). J Clin Oncol. 1985;3:1640–1658
  5. Whelan TJ, Julian J, Wright J, et al.  Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol. 2000;18:1220–1229
  6. Harris JR, Halpin-Murphy P, McNeese M, et al.  Consensus statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys. 1999;44:989–990
  7. Early Breast Cancer Trialists’ Collaborative Group . Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer (An overview of the randomised trials). Lancet. 2000;355:1757–1770
  8. Fisher B, Jeong J-H, Anderson S, et al.  Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347:567–575
  9. Veronesi U, Cascinelli N, Mariani L, et al.  Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347:1227–1232
  10. Fisher B, Anderson S, Bryant J, et al.  Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–1241
  11. Fisher B, Dignam J, Wolmark N, et al.  Lumpectomy and radiation therapy for the treatment of intraductal breast cancer (Findings from National Surgical Adjuvant Breast and Bowel Project B-17). J Clin Oncol. 1998;16:441–452
  12. Galper S, Gelman R, Recht A, et al.  Second nonbreast malignancies after conservative surgery and radiation therapy for early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2002;52:406–414
  13. Fowble B, Hanlon A, Freedman G, et al.  Second cancers after conservative surgery and radiation for stages I-II breast cancer (Identifying a subset of women at increased risk). Int J Radiat Oncol Biol Phys. 2001;51:679–690
  14. Obedian E, Fischer DB, Haffty BG. Second malignancies after treatment of early-stage breast cancer (Lumpectomy and radiation therapy versus mastectomy). J Clin Oncol. 2000;18:2406–2412
  15. Rubino C, de Vathaire F, Diallo I, et al.  Increased risk of second cancers following breast cancer (Role of the initial treatment). Breast Cancer Res Treat. 2000;61:183–195
  16. Fraass BA, Roberson PL, Lichter AS. Dose to the contralateral breast due to primary breast irradiation. Int J Radiat Oncol Biol Phys. 1985;11:485–497
  17. Storm HH, Anderson M, Boice JD, et al.  Adjuvant radiotherapy and risk of contralateral breast cancer. J Natl Cancer Inst. 1992;84:1245–1250
  18. Boice JD, Harvey EB, Blettner M, et al.  Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med. 1992;326:781–785
  19. Hankey BF, Curtis RE, Naughton MD, et al.  A retrospective cohort analysis of second breast cancer risk for primary breast cancer patients with an assessment of the effect of radiation therapy. J Natl Cancer Inst. 1983;70:797–804
  20. Shapiro CL, Mauch PM. Radiation-associated breast cancer after Hodgkin’s disease (Risks and screening in perspective). J Clin Oncol. 1992;10:1662–1665
  21. Morrow MH. Local management of invasive cancer. In:  Harris J,  Lippman ME,  Morrow M, et al. editor. Diseases of the Breast. Philadelphia, PA: Lippincott Williams & Wilkins; 2001;p. 515–560
  22. Neugut AI, Weinberg MD, Ahsan H, et al.  Carcinogenic effects of radiotherapy for breast cancer. Oncology (Huntington). 1999;13:1245–1256
  23. Curtis RE, Boice JD, Stovall M, et al.  Leukemia risk following radiotherapy for breast cancer. J Clin Oncol. 1989;7:21–29
  24. Chaplain G, Milan C, Sgro C, et al.  Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer (A population-based study). J Clin Oncol. 2000;18:2836–2842
  25. Curtis RE, Boice JC, Stovall M, et al.  Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med. 1992;326:1745–1751
  26. Smith RE, Bryant J, DeCillis A, et al.  Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer (The National Surgical Adjuvant Breast and Bowel Project experience). J Clin Oncol. 2003;21:1195–1204
  27. Taghian A, de Vathaire F, Terrier P, et al.  Long-term risk of sarcoma following radiation treatment for breast cancer. Int J Radiat Oncol Biol Phys. 1991;21:361–367
  28. Yap J, Chuba PJ, Thomas R, et al.  Sarcoma as a second malignancy after treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2002;52:1231–1237
  29. Marchal C, Weber B, de Lafontan B, et al.  Nine breast angiosarcomas after conservative treatment for breast carcinoma (A survey from French Comprehensive Cancer Centers). Int J Radiat Oncol Biol Phys. 1999;44:113–119
  30. Strobbe LJA, Peterse HL, van Tinteren H, et al.  Angiosarcoma of the breast after conservation therapy for invasive cancer, the incidence and outcome. An unforseen sequela. Breast Cancer Res Treat. 1998;47:101–109
  31. Neugut AI, Robinson E, Lee WC, et al.  Lung cancer after radiation therapy for breast cancer. Cancer. 1993;71:3054–3057
  32. Neugut AI, Murray T, Santos J, et al.  Increased risk of lung cancer after breast cancer radiation therapy in cigarette smokers. Cancer. 1994;73:1615–1620
  33. Inskip P, Stovall M, Flannery J. Lung cancer risk and radiation dose among women treated for breast cancer. J Natl Cancer Inst. 1994;86:983–988
  34. Rubino C, de Vathaire F, Diallo I, et al.  Radiation dose, chemotherapy and risk of lung cancer after breast cancer treatment. Breast Cancer Res Treat. 2002;75:15–24
  35. Prochazka M, Granath F, Ekbom A, et al.  Lung cancer risks in women with previous breast cancer. Eur J Cancer. 2002;38:1520–1525
  36. Zablotska LB, Neugut AI. Lung carcinoma after radiation therapy in women treated with lumpectomy or mastectomy for primary breast carcinoma. Cancer. 2003;97:1404–1411
  37. Ahsan H, Neugut AI. Radiation therapy for breast cancer and increased risk for esophageal carcinoma. Ann Intern Med. 1998;128:114–117
  38. Early Breast Cancer Trialists’ Collaborative Group . Polychemotherapy for early breast cancer (An overview of the randomised trials). Lancet. 1998;352:930–942
  39. Holdener EE, Nissen-Meyer R, Bonadonna G, et al.  Second malignant neoplasms in operable carcinoma of the breast. Recent Results Cancer Res. 1984;96:188–196
  40. Arriagada R, Rutqvist LE. Adjuvant chemotherapy in early breast cancer and incidence of new primary malignancies. Lancet. 1991;338:535–538
  41. Valagussa P, Moliterni A, Terenziani M, et al.  Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer. Ann Oncol. 1994;5:803–808
  42. Herring MK, Buzdar AU, Smith TL, et al.  Second neoplasms after adjuvant chemotherapy for operable breast cancer. Am J Clin Oncol. 1986;9:269–275
  43. Rubagotti A, Perrotta A, Casella C, et al.  Risk of new primaries after chemotherapy and/or tamoxifen treatment for early breast cancer. Ann Oncol. 1996;7:239–244
  44. Leone G, Voso MT, Sica S, et al.  Therapy related leukemias: Susceptibility, prevention and treatment. Leuk Lymphoma. 2001;41:255–276
  45. Leone G, Mele L, Pulsoni A, et al.  The incidence of secondary leukemias. Haematologica. 1999;84:937–945
  46. Ahuja HG, Felix CA, Aplan PD. Potential role for DNA topoisomerase II poisons in the generation of t(11;20)(p15;q11) translocations. Genes Chromosomes Cancer. 2000;29:96–105
  47. Felix CA. Leukemias related to treatment with DNA topoisomerase II inhibitors. Med Pediatr Oncol. 2001;36:525–535
  48. Tallman MS, Gray R, Bennett JM, et al.  Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: The Eastern Cooperative Oncology Group experience. J Clin Oncol. 1995;13:1557–1563
  49. Diamandidou E, Buzdar AU, Smith TL, et al.  Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy (The University of Texas M.D. Anderson Cancer Center experience). J Clin Oncol. 1996;14:2722–2730
  50. Wils JA, Bliss JM, Marty M, et al.  Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer (A randomized trial of the International Collaborative Cancer Group). J Clin Oncol. 1999;17:1988–1998
  51. Fumoleau P, Kerbrat P, Romestaing P, et al.  Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol. 2003;21:298–305
  52. Levine MN, Bromwell VH, Pritchard KI, et al.  Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosophamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol. 1998;16:2651–2658
  53. Henderson IC, Berry DA, Demetri GD, et al.  Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976–983
  54. Citron ML, Berry DA, Cirrincione C, et al.  Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol. 2003;21:1431–1439
  55. Fisher B, Anderson S, DeCillis A, et al.  Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer (Findings from National Surgical Adjuvant Breast and Bowel Project B-25). J Clin Oncol. 1999;17:3374–3388
  56. Fisher B, Anderson S, Wickerham DL, et al.  Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer (Findings from National Surgical Adjuvant Breast and Bowel Project B-22). J Clin Oncol. 1997;15:1858–1869
  57. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators—Mechanisms of action and application to clinical practice. N Engl J Med. 2003;348:618–629
  58. Early Breast Cancer Trialists’ Collaborative Group . Tamoxifen for early breast cancer (An overview of the randomised trials). Lancet. 1998;351:1451–1467
  59. Fisher B, Costantino JP, Wickerham DL, et al.  Tamoxifen for prevention of breast cancer (Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study). J Natl Cancer Inst. 1998;90:1371–1388
  60. Fisher B, Dignam J, Wolmark N, et al.  Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353:1993–2000
  61. Fisher B, Anderson S, Tan-Chiu E, et al.  Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer (Findings from National Surgical Adjuvant Breast and Bowel Project B-23). J Clin Oncol. 2001;19:931–942
  62. Fisher B, Bryant J, Dignam JJ, et al.  Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol. 2002;20:4141–4149
  63. Fisher B, Costantino J, Redmond C, et al.  A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320:479–484
  64. Fisher B, Costantino JP, Redmond CK, et al.  Endometrial cancer in tamoxifen-treated breast cancer patients (Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14). J Natl Cancer Inst. 1994;86:527–537
  65. Bergman L, Beelen MLR, Gallee MPW, et al.  Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet. 2000;356:881–887
  66. Fornander T, Hellstrom AC, Moberger B. Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst. 1993;85:1850–1855
  67. Magriples U, Naftolin F, Schwartz PE, et al.  High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol. 1993;11:485–490
  68. Fisher B, Dignam J, Bryant J, et al.  Five versus more than five years of tamoxifen for lymph node-negative breast cancer (Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial). J Natl Cancer Inst. 2001;93:684–690
  69. Stewart HJ, Forrest AP, Everington D, et al.  Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer. 1996;74:297–299
  70. Federation Nationale des Centres de Lutte Contre le Cancer Breast Group Delozier T, Spielmann M, Mace-Lesech J, et al.  Tamoxifen adjuvant treatment duration in early breast cancer: Initial results of a randomized study comparing short-term treatment with long-term treatment. J Clin Oncol. 2000;18:3507–3512
  71. Cummings SR, Eckert S, Krueger KA, et al.  The effect of raloxifene on risk of breast cancer in postmenopausal women (Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation). JAMA. 1999;281:2189–2197
  72. Arimidex Study Group Nabholtz JM, Buzdar A, Pollak M, et al.  Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women (Results of a North American multicenter randomized trial). J Clin Oncol. 2000;18:3758–3767
  73. Mouridsen H, Gershanovich M, Sun Y, et al.  Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer (Results of a phase III study of the International Letrozole Breast Cancer Group). J Clin Oncol. 2001;19:2596–2606
  74. Ellis MJ, Coop A, Singh B, et al.  Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer (Evidence from a phase III randomized trial). J Clin Oncol. 2001;19:3808–3816
  75. The ATAC (Anastrazole, Tamoxifen Alone or in Combination) Trialists’ Group . Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer (First results of the ATAC randomised trial). Lancer. 2003;359:2131–2139
  76. Winer EP, Hudis C, Burstein HJ, et al.  American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer (Status report 2002). J Clin Oncol. 2002;20:3317–3327
  77. Chlebowski RT, Col N, Winer EP, et al.  American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol. 2002;20:3328–3343
  78. Hudis C. Breast cancer and leukemia (The forest for the trees?). Ann Surg Oncol. 2002;9:717–718
  79. Van de Vijver MJ, He YD, van’t Veer LJ, et al.  A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009

PII: S0093-7754(03)00472-X

doi: 10.1053/j.seminoncol.2003.08.022

Seminars in Oncology
Volume 30, Issue 6 , Pages 740-748 , December 2003

Article Tools